Indication For Cytoreductive Therapy In Et And Pv: Do We Have It Right

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Cytoreductive therapy for patients with PV

VJHemOnc – Video Journal of Hematology & HemOnc

Considerations for Starting Cytoreductive Therapy in PV

Targeted Oncology

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

Treatment goals in Essential Thrombocythemia and Polycythemia vera

Development of long-acting interferon as new therapy for PV and ET

What Factors Guide Treatment Choices for ET, PV & MF?

Patient Empowerment Network

Treatment for PV: Moving Beyond Hydroxyurea

Targeted Oncology

Current therapy options and clinical outcomes analysis in patients with PV

Case study: Inadequately controlled Polycythemia Vera (PV)

Which Cytoreductive Therapy before Transplant for MDS?

Evolution of the Assessment of Clinical Benefit in Polycythemia Vera

How does assessing risk in polycythemia vera (PV) help you design treatment plans?

Understanding Treatments for MPNs: Are There New or Emerging Treatments That Could Be Right For Me

Patient Empowerment Network

What is the unmet medical need of patients with PV and ET?

VJHemOnc – Video Journal of Hematology & HemOnc

Which MPN Treatment Is Right for You? What You Need to Know

Patient Empowerment Network

Srdan Verstovsek, MD, PhD: The Risk of Thrombosis in PV

What Are Treatment Options for Essential Thrombocythemia (ET) & Polycythemia Vera (PV)?

Patient Empowerment Network

Combination Therapy with JAK2 inhibitors in MPN

Managing PV - Dr. Richard Silver

MPN Education Foundation